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Quantitative prediction of long-
term molecular response in TKI-
treated CML – Lessons from 
an imatinib versus dasatinib 
comparison
Ingmar Glauche  1, Matthias Kuhn  1, Christoph Baldow1, Philipp Schulze1, Tino Rothe1, 
Hendrik Liebscher1, Amit Roy  2, Xiaoning Wang2 & Ingo Roeder  1,3
Longitudinal monitoring of BCR-ABL transcript levels in peripheral blood of CML patients treated with 
tyrosine kinase inhibitors (TKI) revealed a typical biphasic response. Although second generation TKIs 
like dasatinib proved more efficient in achieving molecular remission compared to first generation TKI 
imatinib, it is unclear how individual responses differ between the drugs and whether mechanisms 
of drug action can be deduced from the dynamic data. We use time courses from the DASISION trial 
to address statistical differences in the dynamic response between first line imatinib vs. dasatinib 
treatment cohorts and we analyze differences between the cohorts by fitting an established 
mathematical model of functional CML treatment to individual time courses. On average, dasatinib-
treated patients show a steeper initial response, while the long-term response only marginally differed 
between the treatments. Supplementing each patient time course with a corresponding confidence 
region, we illustrate the consequences of the uncertainty estimate for the underlying mechanisms of 
CML remission. Our model suggests that the observed BCR-ABL dynamics may result from different, 
underlying stem cell dynamics. These results illustrate that the perception and description of CML 
treatment response as a dynamic process on the level of individual patients is a prerequisite for reliable 
patient-specific response predictions and treatment optimizations.
Chronic myeloid leukemia (CML) is a disease characterized by the expression of the BCR-ABL fusion protein in 
virtually all malignant cells in the vast majority of patients1. The affected leukemic stem cells have a competitive 
advantage over normal cells, leading to an initially slow but sustained expansion of the leukemic cell population. 
Untreated, the primary chronic phase (CP) of the disease eventually transforms into an accelerated phase fol-
lowed by an acute blast crisis (BC), in which differentiation of functional blood cells is impaired and, therefore, 
physiological blood function is severely constrained, leading to the patient’s death if left untreated.
It is the molecular specificity of the BCR-ABL fusion gene that forms the basis of a highly efficient, targeted 
therapy by tyrosine kinase inhibitors (TKI). Already the introduction of the first-generation TKI imatinib signif-
icantly improved the treatment prognosis and increased five-year survival levels above 95%2. The availability of 
second-generation (dasatinib, nilotinib) and third-generation TKIs (e.g. bosutinib, ponatinib) further increased 
therapeutic options, including the treatment of a broad spectrum of secondary TKI resistant mutations3. Based on 
the success of TKIs, CML has developed into a showcase example for an efficient, targeted tumor therapy.
Although efficient treatment options are available, predicting the treatment success for a particular patient is 
still a challenge. In clinical practice, prognostic scores like the EUTOS, Sokal or Euro scores are commonly used 
to estimate a patient’s early response (e.g. achieving complete cytogenetic remission at 18 months) to front line 
TKI therapy4. Similarly, the molecular response at specific landmarks, such as three or six months of therapy, is 
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measured in the peripheral blood using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
and used to distinguish treatment responders from non-responders5,6. Alternatively, a more dynamic perspective 
on therapy responses is taken by scores that address the “velocity of leukemia eradication”, such as ratios in the 
levels at two time points7 or the halving time of the tumor load8–10. Although these measures can be used to pre-
dict the average response probability of the particular treatment, none of them addresses the individual molecular 
long-term response in terms of its dynamic appearance or the individual risk of a late molecular relapse.
Considering BCR-ABL dynamics instead of using fixed time points for molecular response evaluation is a fur-
ther alternative to describe treatment efficiency. Longitudinal qRT-PCR based monitoring of molecular response 
revealed that in most patients TKI treatment induces a biphasic decline of BCR-ABL transcript levels, which can 
be characterized by an initially steep decline, followed by a secondary moderate decline. While the first decline 
may result from the rapid depletion of actively cycling BCR-ABL positive leukemic cells, the second decline most 
likely represents the slow elimination of quiescent residual leukemic stem cells (LSC), which are less susceptible 
to cell kill due to their comparatively low cell cycle activity11,12. Following this line of argument, we support 
a dynamic description of the BCR-ABL response to characterize and predict long-term disease and treatment 
dynamics in individual patient, as previously suggested11–14.
Although the use of BCR-ABL dynamics in principle allows for a detailed characterization of the molecular 
response of individual patients, it is based on measurements obtained from the peripheral blood. Therefore, it 
has at least no direct implication for residual disease levels in the stem cell compartment within the bone mar-
row, which is clinically hard to assess. For that reason, we combine the statistical with a mechanistic model. This 
strategy allows us to statistically estimate patient-specific residual disease levels in the peripheral blood, even 
after the PCR monitoring has fallen below its quantification limit. At the same time, it enables us to estimate the 
treatment dynamics at the level of stem cells within the bone marrow, by describing the mechanisms of (stem) 
cell proliferation, differentiation and TKI effects. Specifically, our mechanistic modeling approach11,14,15 assumes 
two effects of the TKI therapy. First, it induces a BCR-ABL specific cytotoxic effect, while, secondly, it reduces 
the proliferative activity of leukemic stem cells. These assumptions are supported by clinical and experimental 
findings16–19. Obviously, the long-term follow-up of TKI treatment20 and clinical stop trials21–23 support the notion 
of a persisting pool of residual stem cells that rarely proliferate and only occasionally contribute to the peripheral 
blood at a minor or even undetectable level. We argue that under TKI treatment the pool of residual leukemic 
stem cells still undergoes a steady, albeit slow reduction in size. However, even after a long treatment time, a 
(dormant) reservoir may remain, which could lead to molecular relapses.
Here, we analyze response dynamics of 519 CML patients in chronic phase (CP) treated within the DASISION 
study, a randomized controlled clinical trial comparing first-line imatinib with dasatinib treatment24. Beside a 
rigorous statistical comparison of the molecular response dynamics, we describe an efficient method for apply-
ing our mechanistic mathematical model of TKI-treated CML to describe individual patient dynamics includ-
ing appropriate confidence regions. Consequently, robust predictions for the molecular long-term response of 
imatinib- and dasatinib-treated patients are derived.
Methods
Clinical Data. The DASISION study (CA180-056, NCT00481247) is a multi-center, randomized trial to 
investigate the response of treatment-naïve CP-CML patients (N = 519) medicated daily with either imatinib 
(median dose was 400 mg with a range of 125 to 741 mg) or dasatinib (median dose was 99 mg with a range of 21 
to 139 mg)25. The primary endpoint was the confirmed complete cytogenetic remission (cCCyR) by 12 months. 
Secondary endpoints included rates of CCyR and MMR, times to CCyR and MMR, as well as progression free and 
overall survival. The data set available for statistical analysis and modeling is based on the minimum follow-up 
of 5 years, analyzed for 259 dasatinib- and 260 imatinib-treated patients. The molecular response was assessed by 
reporting BCR-ABL transcript levels obtained from real-time quantitative polymerase chain reaction (RQ-PCR). 
The assay was performed in a centralized lab and data is normalized to the international scale (IS) with ABL 
being the reference gene. Molecular analysis was performed at baseline (month 0) and then every three months 
after treatment was initiated until month 24. Thereafter, the molecular assessment was conducted at least every 6 
months until the end of study or disease progression.
In order to reliably estimate dynamic parameters of the treatment response (i.e. BCR-ABL decline slopes), 
we restricted our analysis to those patients that conform to the following criteria, denoted as “statistics filter”: 
(1) minimum of 5 time points evaluated, (2) at least two BCR-ABL/ABL measurements within first 4.5 months 
(to ensure estimation of the initial slope), (3) first BCR-ABL/ABL measurements prior or within first 15 days 
after treatment start (to ensure an estimate of the initial tumor load), (4) minimal follow up at least 18 months 
(to ensure a reliable estimation of the secondary slope), (5) no periods larger than 24 months without availa-
ble BCR-ABL/ABL measurements (to exclude rarely monitored patients). Applying this selection, a total of 383 
patients (193 in dasatinib arm (75% of allocated), 190 in imatinib arm (73% of allocated)) were retained and used 
in the statistical analysis. As our mechanistic mathematical model (see below) is only able to describe dynamic 
responses with a bi-phasic decline, i.e. the initial BCR-ABL decline α is steeper compared to the second decline β, 
we applied a further selection strategy (“model filter”): (6) initial slope (α) > secondary slope (β) > 0 (a detailed 
explanation of the slopes is provided below). Finally, the quantification of the prediction accuracy is only realized 
for patients, which fulfill criterion (7) a complete 5 year follow up (“prediction filter”). A summary of the data 
analysis/modelling inclusion criteria along with the actually used patient numbers is provided in Fig. 1.
Statistical analysis. To quantify a patient’s treatment response, we use the corresponding BCR-ABL tran-
script levels, described by the logarithm of the relative abundance (in %) of the BCR-ABL transcript, i.e. 
LRATIO = log10(BCR-ABL/ABL * 100). The nonlinear relationship between the time under treatment (t) and the 
LRATIO per patient are modelled by the logarithm of a bi-exponential function, i.e.: LRATIO(t) = log10 
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(A−αt + B−βt), with parameters A, B, α, and β and the convention that A > B > 0 to make the parameters unam-
biguous. The bi-exponential function on the log-scale resembles a smoothed version of a piecewise linear func-
tion with a single break point (cf.14). The parameters A and B can be interpreted as the intercepts of the two 
approximating line segments, while α and β represents the slopes of these lines (Fig. 2A). We constrain α > 0 to 
reflect the expected initial decline. The parameter β was not restricted (i.e. β ∈ ), allowing for either a decrease 
or an increase in BCR-ABL levels in the second phase (cf.12).
For the assessment of treatment differences between imatinib and dasatinib therapy, we apply a 
population-based non-linear mixed effect (NLME) model using a maximum likelihood (ML) estimation. The 
model selection, i.e. the decision which terms to include in the final NLME-model, is guided by Akaike informa-
tion criterion (AIC). We apply Wald tests to assess statistical significance of model parameters. To fit the 
bi-exponential function to the measurements for each individual patient i, we used the non-linear least squares 
method instead of the patient-level predictions of the NLME model, obtaining a fit that minimizes the residual 
squared errors for each patient. In both routines (population- and patient-based), BCR-ABL values below the 
quantification limit (QL) of the RQ-PCR, are treated as (left-)censored values. I.e., we assume that the true 
BCR-ABL level is at least as low as the QL, but it could also be lower. We refer to the estimated parameter tuple as 
ρ α β=τ A B( , , , )î  and to the residual variance as σi
2. Confidence intervals for the mean LRATIO-value at a given 
time point are calculated via parametric bootstrap. For technical details see Supplementary Methods.
To fit and evaluate the NLME model, we applied the software “Monolix” (version 2018R1)26. All other statis-
tical evaluations were done using the statistical programming environment R27. For further technical details, we 
refer to the Supplementary Methods.
Mechanistic model. Model structure and implementation. CML is modeled as a clonal competition phe-
nomenon between normal hematopoietic and leukemic (stem) cells (Fig. 2B). This concept is implemented as a 
single cell-based model that was originally developed to describe murine hematopoiesis28,29. By upscaling the 
stem cell number and adapting cell turnover rates (see11 for details), the model has been successfully applied to 
the human situation, in particular to CML pathogenesis and treatment11,14,15,30. In order to explain the competitive 
Figure 1. Data flowchart. The flowchart illustrates the selection process of patient data for statistical and model 
analyses.
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advantage of untreated leukemic cells compared to normal HSCs, we assume an increased, unregulated prolifer-
ative activity of leukemic cells. The treatment of CML patients with TKI is assumed to induce a specific cytotoxic 
effect and an inhibition of the proliferative activity of leukemic stem cells (Fig. 2B, indicated in red). Technically, 
the cytotoxic effect is modeled by a selective kill of a fixed percentage of TKI affected leukemic cells per time step 
(degradation rate rdeg), while the proliferation inhibition is modeled by a reduction of the activation of leukemic 
cells into cycle (reduced activation function ωf
CML). In order to adapt our model to the initial patient’s response 
during the first six months of treatment we assume a gradual onset of the effect of TKI activity. Technically, this is 
implemented as a rate (rtrans) describing how fast LSCs are affected by the TKI (i.e, transition rate from a naïve to 
a TKI-affected state). We do not assume a mechanistic difference between the effect of imatinib and dasatinib in 
the model, but we consider the patient-specific treatment response as the result of an individual tumor growth 
Figure 2. Statistical und mechanistic model. (A) Bi-exponential model for the description of time course data, 
parameterized by the intercepts A, B, and the initial slope α and the secondary slope β. (B) Model setup of the 
mechanistic, single-cell based clonal competition model of CML pathogenesis and treatment. Leukemic cells 
are shown in blue, normal cells in grey. Both cell types change between a state of proliferative inactivity (A) and 
a proliferative state (Ω) before cells differentiate into peripheral blood. TKI activity is indicated by the cytotoxic 
effect and the prolonged quiescence of leukemic stem cell in state A. The five parameters modified for the 
simulation screen are identified by roman numerals (i)–(v).
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rate and an individual TKI response, which might quantitatively differ between patients and/or their treatment 
scenario. The tumor load in the peripheral blood, which is clinically measured in terms of BCR-ABL transcript 
levels, is approximated in the mathematical model by the proportion of leukemic (i.e. BCR-ABL positive) cells in 
the population of fully differentiated cells according to the following equation:
≈ + ⋅ .‐ n n nBCR ABL/ABL ( /( 2 )) 100%1 1 2
Herein, n1 denotes the number of leukemic cells and n2 the number of normal cells31. Further details of the model 
implementation are provided in the Supplementary Methods.
Parameter estimation. To derive a consistent model fit for an individual patient, we previously used the same 
mechanistic model14. However, the optimization procedure comprised the variation of two parameters only, 
namely (i) the patient specific degradation rate rdeg and (ii) the activation function ωf
CML. Meanwhile, it became 
evident that also the influence of further treatment- and patient-specific parameters cannot be neglected. Beyond 
(iii) the rate of gradual TKI onset (rtrans), we identified  (iv) the initial tumor load at therapy start (described by the 
LRATIO at time point t = 0, LRATIOinit) and (v) the rate by which leukemic stem cells re-enter into quiescence 
(deactivation, αf
CML) to be additional sensitive determinants of the response dynamics (illustrated in Fig. 2B). For 
reasons of efficiency, we realized a systematic, large-scale screen of a defined parameter space and deposited the 
results in a look up table. In brief, for each of the five parameters (i–v), we determined a plausible range, subdi-
vided the corresponding intervals and assigned 10 (LRATIOinit), 16 (rdegrdeg), 13 (rtrans), 10 ( ωf
CML) and 13 ( αf
CML) 
values at which we evaluated the model in all combinations. This resulted in the set Θ of 270,400 different param-
eter configurations ϑ = ω αf(f , , r , LRATIO , r )
CML CML
deg init trans .
In order to determine the set Θ
τ

i  of suitable parameter configurations of the mechanistic model that fit the time 
course of BCR-ABL/ABL levels for patient i, we apply the following strategy: (1) We derive the bi-exponential fit îρ
τ 
according to an optimization routine (see Supplementary Methods) for the clinically available BCR-ABL levels up 
to time τ. Furthermore, we provide corresponding point-wise 95%-confidence intervals for the fit ρ̂ τi . (2) Using the 
above described look-up table, we identify all parameter configurations of the mechanistic model, for which the 
bi-exponential fit of the model-predicted BCR-ABL time courses are completely contained within the statistically 
determined confidence region (mechanistic model fitting). These identified tuples constitute the set of suitable 
parameter configurations Θ
τ

i . We order the simulated BCR-ABL dynamics in Θ
τ

i according to their distance (sim-
ilarity) to the bi-exponential fit of the data îρ
τ and refer to ϑ
τ

i  as the optimal (best-fitting) parameter configuration 
in Θ
τ

i . Further technical details are provided in the Supplementary Methods.
Cross validation for the prediction accuracy. In order to quantify the prediction accuracy of our mechanistic 
model, we compare the set of suitable parameter configurations from “reduced” data sets, i.e. for a 2, 3 or 4 year 
BCR-ABL monitoring (Θi
y2
, Θi
y3
, Θi
y4
), respectively, with the suitable parameter configurations for the complete 
5-year follow-up Θi
y5
. Specifically, we determine the overlap of 5-year predictions for BCR-ABL levels based on 
Θi
y5
with predictions based on the reduced observation periods Θ
<

i
y5
. Now, we categorize the predictions by eval-
uating the overlap of the predicted confidence intervals at the end of the 5-year period (Supplementary Fig. S2). 
We denote 5-year predictions as true positives (TP) that are within the confidence intervals at 5 years determined 
by both the reduced as well as the complete data set. True negatives (TN) are defined as predictions being neither 
within the confidence interval at 5 years derived from the reduced nor the complete data set. False positives (FP) 
are predictions that are within the confidence interval determined by the reduced data set, but not within the 
confidence interval at 5 years determined by the complete data set. False negatives (FN) refer to predictions that 
are not within the confidence intervals derived from the reduced data set but within the confidence interval deter-
mined by the complete data set.
Availability of data and material. Data are available from the authors upon reasonable request and with 
permission of Bristol-Myers Squibb.
Results
Comparing average treatment response of dasatinib vs. imatinib. Individual treatment responses 
in both arms of the DASISION trial show a considerable degree of heterogeneity between individual patients 
(Fig. 3A, Supplementary Fig. S3). However, the typical bi-phasic BCR-ABL dynamic is observed in the majority of 
patients. This also holds true for a mean time course of the patients in the two treatment arms (Fig. 3B). Although 
the molecular response dynamics for imatinib and dasatinib are qualitatively similar, there are quantitative dif-
ferences. We demonstrate statistically significant effects in the average response dynamics (Fig. 3B, Table 1). 
Specifically, dasatinib treatment yields a faster initial reduction of BCR-ABL levels (i.e. significantly larger slope 
parameter α, p < 0.0001). Although, we also observed a difference in the average long-term BCR-ABL decline 
between the two treatments (p = 0.0323), the dasatinib-induced β-slope is only marginally steeper compared to 
imatinib. We did neither detect a statistically significant difference in the initial intercept parameter A, which 
approximates the initial BCR-ABL levels (p = 0.909) nor in the second intercept parameter B (p = 0.361). Our 
findings confirm recently reported results24 that, on average, a major molecular response (i.e. BCR-ABL levels 
<0.1% = MR3) is achieved earlier in the dasatinib arm (after 22 months) compared to the imatinib arm (after 36 
months). These results are robust with respect to uncertainties for BCR-ABL values >10%, potentially induced by 
the use of the ABL reference gene (see Supplement material).
www.nature.com/scientificreports/
6SCIeNTIFIC REPORTS |  (2018) 8:12330  | DOI:10.1038/s41598-018-29923-4
Quantification and prediction of individual treatment responses. Our results show an accelerated, 
more pronounced average initial molecular response in the dasatinib-treated cohort compared to the imatinib 
arm (Fig. 3B). However, on the level of individual patients, there is considerable heterogeneity in the BCR-ABL 
decline dynamics (both, initially and long-term) that exceeds the differences in the mean response between 
the two cohorts (c.f. Fig. 3A, Supplementary Fig. S3). The patients’ heterogeneity is not only reflected in the 
Figure 3. Dynamics of treatment response. (A) Time course data of a random subset of 8 patients per treatment 
cohort. BCR-ABL levels below detection threshold are indicated by open triangles. (B) Time-course of mean 
BCR-ABL levels (±SD) are shown for intervals of 2 months. The lines correspond to the fixed-effect predictions 
of the mean for the imatinib and the dasatinib cohorts. (C) Scatter plot illustrating the missing correlation 
between initial slope α, and secondary slope β for all available, individually fitted patient time courses 
(Spearman correlation [95% confidence interval]: imatinib r = 0.27 [0.13; 0.40], dasatinib: r = 0.17 [0.03; 0.31], 
all: r = 0.24 [0.14; 0.33]).
Parameter Imatinib Dasatinib p-value
A 37.375 n.a.
α 0.674 1.168 <0.0001
B 0.196 n.a.
β 0.039 0.048 0.0323
Table 1. Fixed-effect parameter estimates from the selected non-linear mixed effect model (NLME). Treatment 
differences are considered for slope parameters α and β. p-values for the treatment effect on the bi-exponential 
parameters are based on Wald tests for equality of the two groups. n.a. = not applicable.
www.nature.com/scientificreports/
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BCR-ABL dynamics, it also applies to other prognostic scores or landmarks, such as MR level at 3 or 6 month5,6 
or the halving time8–10. Here, we confirm a close correspondence of halving time and initial BCR-ABL decline 
α with respect to their prognostic value in achieving major or deep molecular response, with a steeper α-slope 
/shorter halving time being related to a better average response (Supplementary Fig. S1). In fact, one can show 
that the halving time is a surrogate measure of the slope of the initial BCR-ABL decline (α) and, thereby, closely 
resembles its predictive value. At the level of individual patients, however, neither a short halving time nor a 
steeper initial BCR-ABL decline guarantees a favorable long-term outcome. The lacking prognostic power of 
the initial treatment response on the individual long-term behavior is also supported by the fact that there is 
no relevant correlation between the initial (α) and the secondary (β) slope of the BCR-ABL dynamics (Fig. 3C, 
Spearman correlation coefficient: r = 0.24). With respect to the treatment failure, also neither the halving time 
(Supplementary Fig. S1) nor the initial slope α (data not shown), are consistently predictive. In contrast, the sec-
ondary β slope allows to identify a subpopulation of patients with a higher rate of progression events both for the 
dasatinib and the imatinib arm (Supplementary Fig. S1).
Taken together, these results show, that an individual, patient-specific prognosis of long-term treatment effi-
ciency is not possible on the basis of early treatment characteristics alone. Therefore, we suggest to combine 
information from early and late treatment dynamics to estimate the patient’s individual response characteristics. 
This strategy, however, would not work in case of incomplete information, e.g. due to short molecular monitor-
ing periods or due to undetectable BCR-ABL levels, which hinder the direct estimation of response dynamics. 
Furthermore, although the BCR-ABL levels in the peripheral blood partially reflect the residual disease levels of 
stem cells, considerable information is lacking to estimate the patient’s long-term response. To overcome these 
insufficiencies, we suggest to combine the statistical description (i.e., the estimation of α and β slopes) with a 
mechanistic modelling approach, which allows to infer the latent stem cell dynamics from the molecular moni-
toring in the peripheral blood and, therefore, to provide better predictions of the individual molecular long-term 
treatment response.
Mechanistic modelling of individual treatment responses. As motivated above, we complement the 
statistical modelling by the application of a mechanistic model of TKI-treated CML patients11,15. In order to esti-
mate patient-specific parameters of the mechanistic model, we previously suggested to use a nonlinear regression 
model that patient-wise relates the estimated initial and long-term slope of the corresponding clinically observed 
BCR-ABL dynamic to a particular value of the two most critical mechanistic model parameters, namely the deg-
radation rate rdeg and the reduced activation function ωf
CML. Although the model provided suitable approxima-
tions, the adaptation failed in some scenarios14. This approach has been considerably improved, such that we are 
now able to provide a consistent model description for all of the considered patients in the IRIS, CML-IV and 
DASISION trials. To achieve this, we systematically varied five key model parameters and simulated BCR-ABL 
time courses for more than 270,000 different parameter combinations ϑ, i.e., generating a large population of 
“virtual patients” (for technical details see Material & Methods and Supplementary Methods). The results of this 
systematic, large-scale parameter screen have been stored in a look-up table and can be used to efficiently identify 
parameter configurations that optimally represent a given, i.e. clinically observed, patient-specific BCR-ABL 
dynamic.
Figure 4A shows the clinically determined BCR-ABL levels of a particular patient i over an observation period 
of almost 5 years alongside with the estimated bi-exponential regression model ρi
y5^  and point-wise confidence 
intervals. Using the above described look-up table, we identified all suitable parameter configurations of the mech-
anistic model Θi
y5
, which generate simulated BCR-ABL dynamics that fall within the estimated confidence region 
(Fig. 4B). Model fits of other DASISION patients are provided in Supplementary Fig. S5. In general, the number of 
parameter configurations within Θ
τ

i  scales with the residual variance σi
2 of the bi-exponential data fit ρ τî . 
In other words, a patient dynamic that closely adheres to a biphasic decline characteristic leads to a narrower con-
fidence band, which contains fewer suitable parameter configurations. In contrast, fluctuating and/or few data 
points lead to a fit with a broader confidence region. A broader confidence region, consequently, usually leads to 
more suitable mechanistic model simulations. This results in greater uncertainty and hampers the identification of 
a unique model explanation.
Comparing the parameters of the best-fitting mechanistic model ϑτi  with the corresponding statistical param-
eters ρ τî , we observe a positive correlation between the rate of the gradual TKI-effect onset (rtrans) and the slope of 
the initial decline α (Fig. 4C). I.e., the model implies that a faster drug action results in an accelerated reduction 
of the initial tumor burden. Furthermore, the cell proliferation activation function ( ωf )
CML correlates with the 
long-term decline (slope β). This suggests that the dynamics of the long-term response are predominantly deter-
mined by the rate of residual LSC activation (Fig. 4D). Because the gradual TKI-effect onset (described by rtrans) 
is only relevant for early time points, our result can be interpreted as follows: The overall TKI-induced kill of 
BCR-ABL positive cells consists of two sub-effects, a background kill rate (described by model parameter rdeg), 
which acts over the entire administration period of a TKI, and an additional effect, which is only acting shortly 
after onset of treatment (described in the model by the combination of rdegand gradual TKI-effect onset rtrans). 
Comparing the parameters for the optimal model fits ϑ
τ

i  for all patients, one observes a tendency towards higher 
rates of gradual TKI-effect onset (rtrans) in the dasatinib cohort, reflecting an accelerated drug response 
(Supplementary Fig. S3). Only minor differences of other model parameters are observed for imatinib- vs. 
dasatinib-treated patients.
Model prediction for long-term treatment dynamics. As introduced above, the set of suitable param-
eter configurations Θ
τ

i  consistently describes the observed treatment dynamics of patient i. However, to support 
clinical decision-making, the model should additionally yield valid predictions for yet unobserved data, e.g. 
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Figure 4. Estimation of model parameters and prediction accuracy. (A) The optimal fit of the bi-exponential 
regression model îρ
τ is shown along with a point-wise confidence interval for one patient i. (B) Identification of 
all parameter configurations Θ
τ

i , for which the bi-exponential fit of the resulting model simulation is contained 
within the confidence region of the patient’s kinetic. (C) Scatter plot relating the initial slope α of each patient’s 
response with the rate of gradual TKI-effect onset (rtrans) obtained for the most suitable model simulation ϑ
τ

i . 
(D) Scatter plot relating the long-term decline β of each patient’s response with the specific activation rate of the 
residual LSC ( ωf )
CML  obtained for the most suitable model simulation ϑ
τ

i . (E) False positives (FP) and false 
negatives (FN) rates for predictions of 5 year outcomes as a function of shorter observation periods (n = 234).
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expected BCR-ABL values beyond the current treatment period τ. To test the quality of model-predicted 
BCR-ABL dynamics based on available clinical data, we compared the predictions Θi
y2
, Θi
y3
, Θi
y4
 derived on the 
basis of a (reduced) 2, 3 and 4 year data follow-up, with the complete 5 year follow-up Θi
y5
 for each eligible patient 
(Supplementary Fig. S2, see also Material and Methods, Supplementary Methods). Figure 4E illustrates that both, 
the false negative rate (FN) and the false positive rate (FP) decline with longer follow up. Consequently, the frac-
tion of correct predictions (i.e. TP + TN) increases. Specifically, our data shows that already predictions derived 
on the basis of 2-year BCR-ABL monitoring are compatible with the 5-year follow-up predictions in more than 
90%, i.e. FP + FN < 10% (see Fig. 4E). To test for result robustness with respect to uncertainty of BCR-ABL/ABL 
ratios >10%, we repeated the analysis for the scenarios in which all these measurements were either 
down-weighted by a factor ½ or omitted from the analysis. No qualitative difference of the results was observed 
(Suppl. Figs S6 and S7).
We would like to point out that the number of suitable parameter sets Θ
τ

i  depends on the variability of the 
data: the broader the confidence region the more parameter configurations (“virtual patients”) are considered to 
be “consistent” with the data. Thus, “consistency” (in the sense used here) and identifiability of the true 
patient-specific parameter configuration are anti-correlated. We suggest to interpret the prediction accuracy (i.e., 
1 - error rates) conditionally on the quality of the data. Meaning, for a particular interpretation, error rates should 
only be compared with a normalization according to the positive values.
Estimating leukemic stem cell dynamics. Beyond the prediction of BCR-ABL dynamics in the periph-
eral blood, a particular advantage of the mechanistic modelling is the ability to predict the underlying stem cell 
dynamics. Thus, the modelling approach in principle allows to derive estimates about the dynamics of leukemic 
(i.e. BCR-ABL positive) stem cells (Fig. 5A). In Fig. 4B we visualize the suitable parameter configurations Θ
τ

i  for 
an individual patient dynamic i. These PB BCR-ABL dynamics may, however, result from very different, underly-
ing stem cell dynamics. As a simple example, a particular, slow decline of BCR-ABL levels in a given patient could 
be generated by a lower toxicity of the TKI or, alternatively, by a more pronounced quiescence of the leukemic 
stem cells. Our model analysis clearly shows that although the dynamics in the peripheral blood might appear 
very similar, the underlying stem cell dynamics can distinctly differ. Figure 5A shows one example of various stem 
cell dynamics which according to the mechanistic model all result into similar PB BCR-ABL dynamics (i.e. sim-
ulations within Θ
τ

i ). Further examples are provided in the Supplement Fig. S4. These results demonstrate that 
even detailed information on the BCR-ABL dynamics in the PB is not always a reliable surrogate measure for the 
residual disease in terms of the remaining leukemic stem cells.
Analyzing the full patient cohort of the DASISION trial, we observed that the residual variance σ
i
2 of the 
model fit (i.e. the “quality” of the data) correlates with the width of the prediction interval for the residual leu-
kemic stem cells ∆ = −( lsc log (lsc ) log (lsc ))10 max 10 min  at 5 years (Fig. 5B). Furthermore, the width of the predic-
tions from the parameter configurations Θ
τ

i  in peripheral blood at 5 years (Δbcr-abl = log10 (bcr-ablmax) − log10 
(bcr-ablmin)) only moderately correlates with the corresponding width of the stem cell level Δlsc (Fig. 5C). 
Reassuring the validity of our approach, we also observed that the maximal number of residual leukemic cells 
inversely correlates with the slope β characterizing the second decline (Fig. 5D). Thus, our model suggests that the 
steepness of the long-term decline of BCR-ABL levels in PB (i.e., β slope) is an indicator of the number of residual 
LSC. A steeper β decline leads to lower residual leukemic stem cell level (given a certain treatment duration).
Given our suggested approach, we are in principle able to derive prediction intervals for the number of resid-
ual leukemic stem cells at any point during TKI treatment, although the uncertainty of this predication is higher 
(larger confidence regions) than for the prediction of residual disease levels in the peripheral blood. To vali-
date the model with respect to its prediction power of residual LSC numbers, it needs to be compared either to 
BCR-ABL levels in the stem cell(-enriched) population of bone marrow cells (which is almost impossible to be 
determined in patients) or to the relapse behavior of patients for which the TKI treatment has been stopped acting 
as a surrogate measure of residual leukemic stem cells. A corresponding model analysis studying the molecular 
relapse risk of patients after TKI stop is currently in progress32.
Discussion
Our statistical analysis of the dynamic (long-term) treatment response of CP-CML patients within the DASISION 
trial demonstrates differences in the average BCR-ABL dynamics between first-line imatinib and dasatinib treat-
ment. Whereas both TKIs show qualitatively similar response dynamics, we demonstrate that dasatinib leads to 
a significantly faster molecular response. On the other hand, the detected difference for the average long-term 
BCR-ABL decline dynamics is small. Although the absolute values for the early BCR-ABL decline are expected to 
differ quantitatively between the use of ABL and other reference genes (such as GUS)33,34, the presented relative 
comparison in the context of a randomized trial does not depend the particular choice of the reference gene.
Our results suggest that although there is also a slight effect on the long-term BCR-ABL decline, the major 
advantage of dasatinib treatment is evident in the early phase of treatment. Here, the second generation TKI is, on 
average, more efficient in reducing the tumor load compared to imatinib. Similar results were also obtained from 
analyzing the primary endpoint of the DASISION trial, which was CCyR after 12 months of therapy35: signifi-
cantly more patients achieved CCyR in the dasatinib arm compared to the imatinib arm (77% vs. 66%, p = 0,007). 
Additionally, the final analysis with the 5-year follow-up data of the DASISION trial showed a constant efficacy 
benefit over time for dasatinib24. This conforms with our second finding, that once the first phase of the typically 
bi-phasic BCR-ABL decline has been completed, the average velocity of further tumor load reduction does only 
marginally differ between the two TKIs. Although dasatinib patients on average more quickly gain deep remis-
sions (such as MR4 or MR4.5), the dynamics of response for treating residual disease differs only slightly between 
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imatinib and dasatinib. Therefore, other criteria, such as side effects, resistance occurrence, or patient compliance 
should be considered as important criteria for a decision on long-term treatment options.
Beyond the statistical results on the quantitative differences in the treatment effects, we also analyzed the 
BCR-ABL dynamics in the context of a mechanistic mathematical model. Our simulation results suggest that the 
above described differences between dasatinib and imatinib treatment are most likely induced by quantitative 
differences in the TKI effects, especially with regard to the initial treatment efficacy. In particular, the higher rates 
of gradual TKI-effect onset (rtrans) in the dasatinib cohort support the notion of a more effective initial therapy.
Our results outline the importance of considering dynamic parameters, such as the velocity of BCR-ABL 
reduction, for predicting the long-term success of the TKI treatment. Whereas response levels at given landmarks 
(e.g. the BCR-ABL level at three or six months after treatment induction) are clinically relevant for the prediction 
of treatment failure and the achievement of major/complete cytogenetic or molecular remission, the importance 
of considering the disease dynamics is becoming more and more evident, in particular, as this reflects the under-
lying mechanisms of disease progression or regression. We and others7,8,11–14 promote the idea to also clinically 
describe CML treatment response as a continuous, patient-specific process, and thereby building the foundation 
of an individualised therapy approach.
Figure 5. Estimating residual stem cell numbers. (A) Variability for predictions of residual leukemic stem cell 
(LSC) numbers for the model simulations Θ
τ

i in Fig. 4A,B. Every green line corresponds to one suitable 
parameter configuration within Θ
τ

i indicated in blue in Fig. 4B. The green coloring scheme indicates the 
distance of the simulation results to the bi-exponential approximation ρ τî of patient i. lscmax and lscmin refer to 
the maximal and minimal number of predicted LSCs at 5 years. (B) Correlation of the residual variance σ
i
2 of 
the model fit (as a measure of data quality) to the variability of the number of predicted LSCs. (C) Correlation of 
the width of the prediction interval in the peripheral blood and the variability of the number of predicted LSCs. 
(D) Correlation of the second slope β of the patient fit ρ τî with the maximal number of predicted LSCs.
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This perception is further substantiated by our analyses to quantify the heterogeneity in the response charac-
teristics of different patients, which exceeds the level of drug induced variability (see Fig. 3). Moreover, we could 
demonstrate that there is no correlation of early and late BCR-ABL dynamics (Fig. 3C) on the level of individual 
patients. This implies that a prediction about the long-term response of a patient cannot be made based on its 
initial response alone. In fact, long-term dynamics can only be approximated if at least a part of the secondary, 
slower slope has been quantified.
By using an established mechanistic model of TKI-treated CML we could demonstrate that optimal param-
eter configurations for describing the treatment response of individual patients can be identified. Furthermore, 
by defining confidence regions for the time courses of BCR-ABL levels, we do not only identify an optimal set 
of parameters, but also a range of scenarios that all adhere with the observed outcome. Using the suggested 
mapping of measured BCR-ABL values onto in silico simulations of the treatment dynamics allows us to provide 
model-based predictions not only of the expected BCR-ABL values in the peripheral blood, but also for the level 
of residual leukemic stem cells in the bone marrow. However, our results also indicate that the peripheral blood 
BCR-ABL levels do not allow to uniquely estimate and, therefore, predict the underlying dynamics at the level of 
leukemic stem cells. We show that similar response dynamics in the peripheral blood can in principle result from 
rather different stem cell dynamics. Although this result (partially) relates to the technical problem of incomplete 
model identifiability, it also points to a more general problem: It theoretically demonstrates that there might be 
biological processes at the stem cell level that cannot be quantified based on BCR-ABL levels in the peripheral 
blood alone, thus calling for the identification of additional biomarkers. Nevertheless, because the number of 
residual leukemic stem cells is most likely the decisive parameter which determines the cure status, our model 
allows in principle to predict the expected time to “real” cure (i.e. elimination of all leukemic stem cells) on the 
basis of a (conservative) confidence interval estimation of residual leukemic stem cells. However, in the context 
of treatment cessation trials it appears that secondary effects like immunological components strongly influence 
long-term disease control. Including those aspects into a quantitative modelling environment requires both a bet-
ter understanding of the mechanistic immune interactions as well as their quantification. Corresponding efforts 
in experimental and conceptual studies are ongoing36,37.
As described above, our approach allows for a robust prediction of the long-term molecular response in 
TKI-treated CML patients. Herein, the quality of the predictions depends considerably on the amount and quality 
of clinically determined BCR-ABL levels. Further limitations of the approach are related to the appearance of TKI 
resistance or disease acceleration. Currently, the model assumes constant treatment effects. Along these lines, also 
effects of non-compliance (i.e., unknown treatment interruptions) are problematic. These are obviously inducing 
altered treatment effects, which cannot be captured by the model, if time point and durations are not known. 
Another problem appears if patients respond “too well”, i.e. if BCR-ABL levels quickly approach the PCR quan-
tification limit and stay negative. Although such patients can be considered as good responders, the long-term 
dynamics can hardly be estimated in these cases. Thus, BCR-ABL negative patients with a persisting BCR-ABL 
decline (below the quantification limit) cannot be distinguished from those that would show a constant albeit 
non-detectable residual disease level. While our approach, on the one hand, can partially account for missing 
information by a compensation from the entire population of similar patients (i.e. mixed-effect modelling), this, 
on the other hand, bears the danger that the specificity of a particular patient is underestimated.
The availability of high quality time course data of tumor load made CML a primary example for many mathe-
matical modeling approaches. Beyond the statistical description of time courses, several models fostered a strong 
discussion about underlying mechanisms of disease and treatment progression such as the role of TKI activity in 
the stem cell compartment11,38–40, the role of cellular quiescence41, combination therapies42,43, resistance occur-
rence44 or the role of the immune system36,45,46. All those models are bound to their underlying set of assumptions, 
which are in many instances motivated by experimental or clinical observations, but need to be understood to 
appreciate the potential and limitations of each model approach. As for our particular model it is the perception 
of CML as a competition process of normal and leukemic cells that simplifies a complex set of regulations and 
escape mechanisms. However, sensitivity analysis and the success of different modeling approaches with slightly 
diverging assumptions ensures us about the validity of our approach and its generalizability.
Our current work illustrates the role for statistical and dynamical modeling of CML to delineate the potential 
and the limitations of systems biological approaches for disease management and treatment optimization. While 
on one side we inherently perceive and describe treatment response as the feature of an individual patient, we, on 
the other side, use the statistical characterization to adapt a mechanistic model of the underlying treatment. This 
step allows to derive predictions about unobserved quantities such as the residual leukemic burden in the bone 
marrow, and thereby builds the basis for patient-specific treatment approaches.
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